MeiraGTx Holdings (Nasdaq:MGTX) - Aktienkurs, Nachrichten und Analyse

MGTX Aktienübersicht

MeiraGTx Holdings plc, ein Gentherapieunternehmen im klinischen Stadium, das sich auf die Entwicklung von Behandlungen für Patienten mit schweren Krankheiten konzentriert.

Über das Unternehmen

MGTX fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	5/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Belohnungen

Prognostiziertes Gewinnwachstum 56.05% pro Jahr

Risikoanalyse

Hat weniger als 1 Jahr Cash Runway

Die Aktionäre wurden im vergangenen Jahr verwässert

MeiraGTx Holdings plc Wettbewerber

Amarin

NasdaqGM:AMRN

US$319.7m

C4 Therapeutics

NasdaqGS:CCCC

US$301.4m

Emergent BioSolutions

NYSE:EBS

US$323.3m

Agenus

NasdaqCM:AGEN

US$324.6m

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for MeiraGTx Holdings
Historical stock prices
Current Share Price	US$4.49
52 Week High	US$7.60
52 Week Low	US$3.49
Beta	1.42
1 Month Change	-21.37%
3 Month Change	-28.50%
1 Year Change	-40.21%
3 Year Change	-71.14%
5 Year Change	-79.09%
Change since IPO	-70.07%

Aktuelle Nachrichten und Updates

Recent updates

MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are Reducing Their Forecasts For This Year

Mar 16

MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are More Bearish Than They Used To Be

Nov 16

MeiraGTx GAAP EPS of -$0.76, revenue of $10.76M

Aug 11

MeiraGTx inks $100M debt agreement backed by manufacturing facilities

Aug 03

MeiraGTx Holdings (NASDAQ:MGTX) Is In A Good Position To Deliver On Growth Plans

Apr 29

Analysts' Revenue Estimates For MeiraGTx Holdings plc (NASDAQ:MGTX) Are Surging Higher

Mar 15

MeiraGTx: Perceptive's Large Stake Makes It Interesting

Jan 19

MeiraGTx Holdings (NASDAQ:MGTX) Is In A Good Position To Deliver On Growth Plans

Dec 28

MeiraGTx: Novel Riboswitch Technology Could Add Value

Nov 01

Shareholders Will Probably Hold Off On Increasing MeiraGTx Holdings plc's (NASDAQ:MGTX) CEO Compensation For The Time Being

Jun 05

MeiraGTx Holdings'(NASDAQ:MGTX) Share Price Is Down 11% Over The Past Year.

Feb 22

Is MeiraGTx Holdings plc (NASDAQ:MGTX) Popular Amongst Insiders?

Jan 18

Aktionärsrenditen

	MGTX	US Biotechs	US Markt
7D	-6.5%	-0.1%	1.0%
1Y	-40.2%	7.1%	20.8%

Rendite im Vergleich zur Industrie: MGTX unter dem Niveau der Branche US Biotechs, die im vergangenen Jahr eine Rendite von 7.4% erzielte.

Rendite vs. Markt: MGTX hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 25.6 erzielte.

Preisvolatilität

Is MGTX's price volatile compared to industry and market?
MGTX volatility
MGTX Average Weekly Movement	5.9%
Biotechs Industry Average Movement	10.3%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.4%
10% least volatile stocks in US Market	2.9%

Stabiler Aktienkurs: MGTXDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: MGTXDie wöchentliche Volatilität (7%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2015	402	Alexandria Forbes	meiragtx.com

MeiraGTx Holdings plc, ein Gentherapieunternehmen im klinischen Stadium, das sich auf die Entwicklung von Behandlungen für Patienten mit schweren Krankheiten konzentriert. Das Unternehmen entwickelt verschiedene Therapien für Augenkrankheiten, einschließlich erblicher Netzhauterkrankungen und großer degenerativer Augenkrankheiten, neurodegenerativer Erkrankungen und Xerostomie. Zu den Programmen in der klinischen Entwicklung gehören Programme der Phase I/II für Achromatopsie, X-chromosomale Retinitis pigmentosa und RPE65-Mangel, klinische Studien der Phase I für strahleninduzierte Xerostomie sowie ein Parkinson-Programm, das eine Phase-II-Studie abgeschlossen hat.

MeiraGTx Holdings plc's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von MeiraGTx Holdings im Vergleich zum Marktanteil des Unternehmens?
MGTX grundlegende Statistiken
Marktanteil	US$288.74m
Gewinn(TTM)	-US$74.10m
Umsatz(TTM)	US$11.38m

25.4x

Kurs-Umsatz-Verhältnis

-3.9x

Kurs-Gewinn-Verhältnis

Ist MGTX zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
MGTX Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$11.38m
Kosten der Einnahmen	US$0
Bruttogewinn	US$11.38m
Sonstige Ausgaben	US$85.49m
Umsatz	-US$74.10m

Zuletzt gemeldete Gewinne

Mar 31, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-1.15
Bruttomarge	100.00%
Nettogewinnspanne	-651.19%
Schulden/Eigenkapital-Verhältnis	59.5%

Wie hat sich MGTX auf lange Sicht entwickelt?

Historische Performance und Vergleiche

MGTX Aktienübersicht

Belohnungen

Risikoanalyse

MeiraGTx Holdings plc Wettbewerber

NasdaqGM:AMRN

US$319.7m

NasdaqGS:CCCC

US$301.4m

NYSE:EBS

US$323.3m

NasdaqCM:AGEN

US$324.6m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Consensus revenue estimates decrease by 11%, EPS upgraded

First quarter 2024 earnings released: US$0.32 loss per share (vs US$0.62 loss in 1Q 2023)

MeiraGTx Holdings plc, Annual General Meeting, Jun 06, 2024

MeiraGTx Holdings plc Appoints Dr. Debra Yu to Serve on Each of the Compensation Committee and Science and Technology Committee of the Board

Price target decreased by 10.0% to US$21.60

New major risk - Financial position

Recent updates

Consensus revenue estimates decrease by 11%, EPS upgraded

First quarter 2024 earnings released: US$0.32 loss per share (vs US$0.62 loss in 1Q 2023)

MeiraGTx Holdings plc, Annual General Meeting, Jun 06, 2024

MeiraGTx Holdings plc Appoints Dr. Debra Yu to Serve on Each of the Compensation Committee and Science and Technology Committee of the Board

Price target decreased by 10.0% to US$21.60

New major risk - Financial position

MeiraGTx: Bota-Vec Program Advancing With Milestones Being Met

CEO, President & Director exercised options and sold US$101k worth of stock

CEO, President & Director exercised options and sold US$587k worth of stock

Forecast to breakeven in 2025

MeiraGTx Holdings plc has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

MeiraGTx Holdings plc announced that it has received $30 million in funding from Sanofi Foreign Participations B.V.

New minor risk - Share price stability

MeiraGTx Holdings plc Announces an Oral Presentation and Eight Posters At the European Society of Gene and Cell Therapy 2023 Annual Congress

Does MeiraGTx Holdings (NASDAQ:MGTX) Have A Healthy Balance Sheet?

Consensus revenue estimates decrease by 12%, EPS upgraded

New major risk - Financial position

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MeiraGTx Holdings plc Announces Positive Clinical Data from the AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

MeiraGTx Holdings plc to Present 12-Month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MeiraGTx Holdings plc announced that it expects to receive $61.525 million in funding from Perceptive Advisors LLC, 683 Capital Management, LLC, Prosight Management, LP, Adage Capital Management, L.P.

Calculating The Intrinsic Value Of MeiraGTx Holdings plc (NASDAQ:MGTX)

MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are Reducing Their Forecasts For This Year

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased by 7.4% to US$31.00

CEO, President & Director exercised options and sold US$222k worth of stock

CEO, President & Director exercised options and sold US$170k worth of stock

MeiraGTx Holdings plc cAnnounces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Consensus revenue estimates fall by 26%

MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are More Bearish Than They Used To Be

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

MeiraGTx Holdings plc announced that it has received $24.999994 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

MeiraGTx GAAP EPS of -$0.76, revenue of $10.76M

MeiraGTx Holdings plc announced that it expects to receive $100 million in funding from Perceptive Advisors LLC

MeiraGTx Holdings plc announced that it expects to receive $100 million in funding from Perceptive Advisors LLC

MeiraGTx inks $100M debt agreement backed by manufacturing facilities

MeiraGTx Holdings plc Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients Treated with Botaretigene Sparoparvovec (AAV-RPGR) Compared to Untreated Randomized Control

Consensus forecasts updated

Price target decreased to US$30.57

MeiraGTx Holdings plc Presents Clinical Data on Botaretigene Sparoparvovec for Treatment of X-Linked Retinitis Pigmentosa at Association for Research in Vision and Ophthalmology 2022 Annual Meeting

MeiraGTx Holdings plc, Annual General Meeting, Jun 07, 2022

MeiraGTx Holdings (NASDAQ:MGTX) Is In A Good Position To Deliver On Growth Plans

MeiraGTx Appoints Debra Yu to Board of Directors

Insufficient new directors

Insufficient new directors

Consensus revenue estimates increase by 28%

Analysts' Revenue Estimates For MeiraGTx Holdings plc (NASDAQ:MGTX) Are Surging Higher

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

MeiraGTx: Perceptive's Large Stake Makes It Interesting

CEO, President & Director exercised options and sold US$1.1m worth of stock

MeiraGTx Holdings (NASDAQ:MGTX) Is In A Good Position To Deliver On Growth Plans

MeiraGTx Announces Positive Preliminary Data from the AQUAx Phase 1 Clinical Trial of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Third quarter 2021 earnings released: US$0.59 loss per share (vs US$0.17 loss in 3Q 2020)

Erträge & Einnahmen